Akira Science
Develops degradable polymer filaments and 3D-printed bioabsorbable scaffolds for soft tissue engineering, enabling personalized medical solutions that promote natural tissue regeneration
- CEO / Founder
- Álvaro Morales López
- Team Size
- 1-10
- Stage
- Active
- Total Funding
- $4.05M
- Latest Round
- Convertible Note
- Key Investors
- Ready2Scale; Vinnova; Stockholm Innovation & Growth; KTH Innovation; KTH Royal Institute of Technology; STING Accelerator
Technology & Products
Key Products
AKIMed-C12 material (medical grade filament); Customized scaffolds for soft tissue engineering; AkiMed™ Breast Implant for breast reconstruction surgery; Technical grade materials for research applications
Technological Advantage
Verified advantage: Proprietary degradable polymer formulations optimized for extrusion-based 3D printing and tissue regeneration; collaboration with EnvisionTEC to validate materials for commercial bioprinters. Defensible through material formulations and processing know-how.
Differentiation
Value Proposition
Provides customized, pliable 3D-printed scaffolds that match patient-specific anatomical requirements while promoting natural tissue regeneration, reducing complications from permanent implants and enabling faster recovery
How They Differentiate
Focuses specifically on degradable polymers for soft tissue engineering rather than permanent implants; combines material science with mechanical simulation for customized scaffold design; offers both ready-to-use filaments and custom scaffold manufacturing services
Market & Competition
Target Customers
Medical researchers, tissue engineering labs, biomedical device manufacturers, hospitals performing reconstructive surgery
Industry Verticals
Medical Devices; Biomedical Research; Regenerative Medicine; Healthcare
Competitors
TissueLabs
Growth & Milestones
Growth Metrics
2 total employees; revenue not disclosed; primary industry is Therapeutic Devices
Major Milestones
Academic spin-off from Swedish research institutions; Development of AKIMed-C12 material platform; Collaboration with EnvisionTEC for material validation; Launch of AkiMed™ Breast Implant product